Expanding Access to Patients in Need Around the World
Interview with Gregg H. Alton, Ph.D., Executive VP, Corporate and Medical Affairs, Gilead Sciences, Inc.
Part 1: Product portfolio and pipeline
355 views
00:06:06 - Uploaded by Essinova on June 20, 2010
(Subtitled in Chinese. Translation by Charles Liu, Ph.D., Gilead Sciences; member of CABS)
At BioPacific2010, Gregg Alton spoke to Essinova host, BeiBei Song about Gilead's HIV/AIDS product portfolio, the company's pipeline status, its global access program and initiatives in Asia.
Tags: CABS, BioPacific 2010, Gregg Alton, Gilead, HIV, AIDS, Viread, Truvada, Atripla, hepatitis C
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Therapeutics & Vaccines
-
Vitae's Computationally-grown Molecules and Four Tough Diseases
-
Expanding Access to Patients in Need Around the World
-
Five Prime Therapeutics - Protein Medicines
-
Chemokine Therapeutics from ChemoCentryx
-
Developing RNAi Therapeutics (Part I)
-
Developing RNAi Therapeutics (Part II)
-
Developing RNAi Therapeutics (Part III)
